| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00486434 | Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis | PHASE3 | COMPLETED | 1,176 | — | — | May 1, 2007 | Sep 1, 2010 | Apr 26, 2019 | 9 | Czechia, Denmark +4 |
The signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24.
WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain).
WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of difficulty for performing each daily function listed in the questionnaire. 0 is no difficulty (best), 100 is extreme difficulty (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 1700. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less difficulty).
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | SMC021 Oral Calcitonin, 0.8 mg twice daily during 24 months |
| 2 | PLACEBO_COMPARATOR | SMC021 Placebo, orally twice daily during 24 months |
| Name | Type | Description |
|---|---|---|
| SMC021 Oral Calcitonin | DRUG | 0.8mg SMC021 (Oral Calcitoinin) twice daily |
| SMC021 Placebo | DRUG | Placebo orally, twice daily |
Inclusion Criteria: * Medical history and symptoms of knee osteoarthritis Exclusion Criteria: * Any other disease or medication affecting the bone or cartilage. * Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering t...